Immediate Impact
12 standout
Citing Papers
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
2022 Standout
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
2021 Standout
Works of A. E. Barclay being referenced
Oral Retinoids and Psoriasis
1978
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| A. E. Barclay | 10 | 5 | 2 | 17 | 12 | 4 | 45 | |
| Chris Nieuwhof | 9 | 2 | 3 | 18 | 12 | 5 | 46 | |
| Luis Trapiella | 12 | 4 | 40 | 16 | 14 | 5 | 48 | |
| Niklas J. Lang | 3 | 8 | 24 | 7 | 2 | 37 | ||
| Zhenhua Gan | 10 | 9 | 3 | 13 | 10 | 3 | 170 | |
| Érica Naomi Naka Matos | 10 | 6 | 17 | 9 | 17 | 4 | 40 | |
| Maiko Kiryu | 4 | 9 | 25 | 17 | 6 | 5 | 228 | |
| Gregory E. Sanda | 6 | 6 | 2 | 21 | 5 | 5 | 36 | |
| Mayret Castillo | 13 | 9 | 6 | 14 | 10 | 5 | 178 | |
| T. Peterson | 10 | 4 | 6 | 7 | 4 | 3 | 174 | |
| Dolcie Paxton | 9 | 7 | 35 | 7 | 20 | 3 | 43 |
All Works
Loading papers...